Montelukast Eg

Montelukast, the active ingredient in Montelukast Eg, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and allergic symptoms.

Asthma: reduces frequency of bronchospasm and improves overall control. Allergic rhinitis: alleviates nasal congestion, sneezing and itching. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate pain often transient. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: occasional dry or productive cough. - Nausea: feeling of queasiness or upset stomach. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis. - Neuropsychiatric events: mood changes, depression, suicidal thoughts. - Hepatic enzyme elevation: increased liver transaminases. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Montelukast, clinicians should observe the following precautions.

- Assess asthma control: ensure baseline control before adding therapy. - Monitor neuropsychiatric symptoms: watch for mood changes or suicidal ideation. - Use caution in hepatic impairment: adjust use if liver disease is present. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Review concomitant CYP3A4 modulators: dose may need adjustment with strong inhibitors or inducers. - Store at room temperature: keep in the original pack, protect from moisture and heat.

Montelukast can interact with other medicines, requiring attention to the interaction level.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase montelukast plasma concentrations. - Concurrent use with other leukotriene receptor antagonists (e.g., zafirlukast): may raise risk of adverse effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce montelukast effectiveness. - Fluoxetine or other SSRIs: may potentiate neuropsychiatric side effects. - NSAIDs: may increase risk of bronchospasm in sensitive individuals. - Warfarin: occasional reports of altered INR, monitor coagulation.